Author

M. C. Richner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Research Focus:variant calling· 1

Frequent Co-Authors

J. M. Richner· 2 shared A. K. Pinto· 1 shared C. J. Wollner· 1 shared J. Class· 1 shared J. D. Brien· 1 shared M. A. Hassert· 1 shared M. Park· 1 shared P. Penaloza-MacMaster· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. M. Richner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2

T. Dangi, S. Sanchez, M. Park, J. Class, M. C. Richner, J. M. Richner, P. Penaloza-MacMaster

This study shows that nucleocapsid-specific antibodies can help control SARS-CoV-2 infection in mice, suggesting their potential inclusion in vaccines and monoclonal therapies.

bioRxiv · Mar 9, 2022 · PreprintImmunology

A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity

C. J. Wollner, M. C. Richner, M. A. Hassert, A. K. Pinto, J. D. Brien, J. M. Richner

This paper develops an mRNA-LNP vaccine against Dengue Virus serotype 1 that elicits strong, serotype-specific immunity with reduced antibody-dependent enhancement.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology